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ABSTRACT  26 
Serotype 19A strains have emerged as a cause of invasive pneumococcal disease after the 27 
introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) and serotype 19A 28 
has now been included in the recent thirteen-valent vaccine (PCV13). Genetic analysis has 29 
revealed at least three different capsular serotype 19A subtypes and nutritional environment 30 
dependent variation of the 19A capsule structure has been reported. Pneumococcal vaccine 31 
effectiveness and serotyping accuracy might be impaired by structural differences in 32 
serotype 19A capsules. We therefore analyzed the distribution of 19A subtypes collected 33 
within a Swiss national surveillance program and determined capsule composition in 34 
different nutritional conditions with high-performance liquid chromatography (HPLC), gas 35 
chromatography – mass spectrometry (GC-MS) and nuclear magnetic resonance 36 
spectroscopy (NMR). After the introduction of PCV7 a significant relative increase of subtype 37 
19A-II and decrease of 19A-I occurred. Chemical analyses showed no difference in the 38 
composition as well as the linkage of 19A subtype capsular saccharides grown in defined 39 
and undefined growth media being consistent with a trisaccharide repeat unit composed of 40 
rhamnose, N-acetyl-mannosamine and glucose. In summary, our study suggests that no 41 
structural variance dependent of the nutritional environment or the subtype exists. The 42 
serotype 19A subtype shift observed after the introduction of the PCV7 can therefore not be 43 
explained by selection of a capsule variant. However, capsule composition analysis of 44 
emerging 19A clones is recommended in cases where there is no other explanation for a 45 
selective advantage such as antibiotic resistance or loss or acquisition of other virulence 46 
factors  47 
  48 
 o
n
 Septem
ber 7, 2016 by Universitaetsbibliothek Bern
http://iai.asm
.org/
D
ow
nloaded from
 
3 
 
INTRODUCTION 49 
The polysaccharide capsule is a major virulence factor of the human pathogen 50 
Streptococcus pneumoniae (pneumococcus) and more than 90 different capsular types are 51 
known today, which differ in the chemical structure of their capsular polysaccharides (1). 52 
These differences are reflected in the type-specific reaction with anticapsular antibodies, by 53 
which a serotype is determined and cross-reactive serotypes are pooled into serogroups.  54 
The serogroup 19 contains, among others, serotypes 19F and 19A, which belong to the 55 
clinically most relevant serotypes (2). Based on both genetic background and chemical 56 
analyses the serotype 19A and 19F oligosaccharide repeating unit structures have been 57 
determined to be trisaccharides of glucose (Glc), rhamnose (Rha) and N-acetyl-58 
mannosamine (ManNAc), differing only in the glycosidic linkage between glucose and 59 
rhamnose: 60 
19F: →2)-α-L-Rha-(1→PO4→4)-β-D-ManNAc-(1→4)-α-D-Glc-(1→   61 
19A: →3)-α-L-Rha-(1→PO4→4)-β-D-ManNAc-(1→4)-α-D-Glc-(1→  (1, 3-5). 62 
Based on chemical analyses two types of 19A oligosaccharide structures have been 63 
described (6, 7). In addition to the genetically proposed structure above, an alternative with a 64 
serotype 19F backbone and two side chains of β-D-GlcNAc-(1→3)-β-D-Gal- (1→P→2) and 65 
α-L-Fuc-(1→P→3)  has been reported based on chemical analysis (7). The polysaccharide 66 
structures appear to vary with different in vitro growth conditions (6). Influence of the 67 
nutritional environment on the pneumococcal polysaccharide capsule could have biological 68 
consequences, as this would potentially impair any intervention or test targeting the 69 
pneumococcal capsule. For example, the fungus Cryptococcus neoformans is known to be 70 
able to change the capsule structure in vitro and also during infection (8-11), and those 71 
changes have been shown to lead to altered antigenicity (8, 11).  72 
Because polysaccharides for pneumococcal vaccine production are derived from in vitro 73 
cultures, a nutrient-dependent variation could lead to antigenic preparations which differ from 74 
the in vivo antigen.  75 
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Capsule variation could also impair diagnostic procedures such as classical serotyping, 76 
which is based on polysaccharide specific antigen-antibody reaction.  77 
Serotype 19A strains have emerged after the introduction of the seven-valent pneumococcal 78 
vaccine, and were subsequently included in the thirteen-valent vaccine now recommended 79 
in most countries (12, 13). The emergence of serotype 19A after the introduction of the 80 
seven-valent vaccine was surprising, as a cross-protection was expected due to close 81 
chemical similarity to the serotype 19F capsule as it was observed for serotypes 6A and 6B 82 
which also differ only by one glycosidic linkage (14, 15). Furthermore, 19F-19A cross-83 
protection had been observed to a certain degree in an animal model (16). Recent work 84 
suggests a conformational difference in polysaccharide structure, which might explain the 85 
reduced cross-protection (17, 18).  86 
At least three different 19A capsule subtypes are known based on the genetic arrangement 87 
of the capsule gene locus compared to a reference strain (19). In addition to various SNPs 88 
along the capsule operon, most characteristically, subtypes I and II have an inverted rmlD 89 
gene, which is the last gene in the rhamnose synthesis pathway (3). To our knowledge, no 90 
variations in the capsule structure have been described for different subtypes.  91 
Given the recent discovery of 19A capsular subtypes and previous reports of structural 92 
variants as well as the introduction of serotype 19A in the 13- valent pneumococcal 93 
conjugate vaccine (PCV13) we aimed to determine the epidemiology and capsule 94 
composition of different 19A subtypes in different nutritional environments.  95 
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MATERIAL AND METHODS 96 
Bacterial strains and serotype 19A subtype analysis. Serotype 19A subtype strains were 97 
selected from a Swiss national pneumococcal surveillance program (20). In order to detect 98 
the different described 19A subtypes (19) we analyzed 158 pneumococcal serotype 19A 99 
isolates derived from the upper respiratory tract of infant and adult outpatients with signs of 100 
upper respiratory tract infection (20). Antimicrobial susceptibility for penicillin, 101 
sulfamethoxazole / trimethoprim (SXT) and erythromycin was determined as previously 102 
described (20). In brief, minimum inhibitory concentration (MIC) for penicillin non-103 
susceptibility was ≥ 0.06 mg/L while for erythromycin and SXT the disk diffusion method was 104 
performed (intermediate and resistant were considered as non-susceptible). A two-step PCR 105 
protocol was used to determine the 19A subtype of each strain using the following 106 
conditions. The first PCR was done with two primer pairs: rmlb_1_f -GAT GGT GAG AAG 107 
AAC AAT AAG; rmlb_2_f - GAC GGT GAG AAG AAC AAC AAG; rmld_1_r- CTT CAT TAC 108 
GTT CAT CCA ATA and rmld_2_r  CAG CTG AAG ACA CCA CTT GGT. PCR conditions 109 
were initial heat activation 6 min 95°C, 30 cycles of 30s 95°C, 20s of 60°C and 90s of 72°C 110 
with a final extension of  5 min 72°C. The reaction mixture contained 2.5 μL of FastStart Taq 111 
reaction buffer without MgCl2, 2.7 μL of 25 mM MgCl2 stock solution, 4 μL of 1.25 mM 112 
deoxynucleoside triphosphates (0.2 mM final), 0.2 μL (1 U) of FastStart Taq polymerase (all 113 
from Roche Molecular Biochemicals, Rotkreuz, Switzerland), and 0.25 μL of each primer 114 
(100 μM stock resulting in 1 μM final concentration, Microsynth AG, Balgach, Switzerland) in 115 
a total volume of 25 μL. PCR products were visualized on 1% agarose gels. A resulting PCR 116 
product of 560 bp indicated subtypes 19A-I and 19A-II whereas a band of 425 bp indicated 117 
subtype 19A-III. For isolates within the first group (19A-I/19A-II), a second PCR reaction was 118 
performed to discriminate between the two groups using the following primers: wzg_2_f -119 
AGT TGA TTC GTC CAT CCA CAC T; wzg_3_f -GGA ATT GAC ACA TAT GGT CCT and 120 
wzh_r -GCC AAG AGA GCC TTG CTT TCC. The resulting PCR products were 654 bp and 121 
833 bp for types 19A-I and 19A-II, respectively.  122 
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Strains were further characterized with plyNCR-RFLP as previously described (21, 22). We 123 
selected the following strains for further analysis of the capsule composition (Table 1): 124 
109.44 and 501.14 (subtype 19A-I), 501.24 (subtype 19A-II), and 412.49 (subtype 19A-III). 125 
For all selected subtype test strains, multi locus sequence typing (MLST) was determined as 126 
previously described (22). In addition, we included the internationally spread Hungary-19A-6 127 
strain (23), which was classified as a 19A III. Serotype 19F strains 505.32 and B201.73 were 128 
selected for comparison as the polysaccharide repeat unit contains the same backbone 129 
monosaccharides but different glycosidic linkages between the repeat units. Both strains are 130 
clinical isolates derived from Swiss national surveillance programs (20, 24). In addition a 131 
capsule knockout mutant of strains B201.73 was generated as previously described (25, 26) 132 
to assess the amount of background signal in capsule extracts. Commercially available 133 
capsule polysaccharide of serotype 19A from the American Type Culture Collection (ATCC, 134 
Molsheim Cedex, France) was used as a reference standard.  135 
Chi-Square and Fisher exact tests were used to calculate p values for epidemiological 136 
analyses. A value of p ≤ 0.05 was considered significant. In addition, we used a multivariate 137 
logistic regression model to ascertain the strength of the association between PCV7 era and 138 
19A subtypes, and adjusted for potential confounders like age (0-1 (base), 2-4, 5-15 and >15 139 
years), sex (male gender as base), penicillin resistance (susceptible chosen as base), 140 
erythromycin resistance (susceptible chosen as base), SXT resistance (susceptible chosen 141 
as base) and geopraphical origin (east Switzerland as base). Adjusted odds ratios (aOR) 142 
with 95% confidence intervals (95%CI) were received (table S1). Trends over time in the 143 
prevalence of different 19A subtypes before the introduction of PCV7 were analyzed using 144 
linear regression. 145 
Growth conditions, polysaccharide purification, hydrolysis and high performance 146 
liquid chromatography (HPLC). Strains were handled and grown as described previously 147 
(25). The undefined growth medium pneumococcal inoculation medium (PIM) which has 148 
been reported to alter 19A capsule composition (6), as well as a chemically defined medium 149 
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(CDM) by van den Rijn and Kessler (27) were used. CDM was supplemented with 5 mg/L 150 
choline chloride (28), but made without monosaccharides to allow modification of the type 151 
and concentration of the carbon source for each experiment. Monosaccharides were added 152 
to the CDM and the mixture was sterile filtrated using a 0.22 µm filter unit (TPP, 153 
Trasadingen, Switzerland). Two forms of CDM were created, one supplemented with 55 mM 154 
Glucose and the other one mimicking the composition of the salivary mucin MG1, i.e.: N-155 
aceteylneuraminic acid (NeuNAc):fucose (Fuc):galactose (Gal):N-acetylglucosamine 156 
(GlcNAc):N-acetylgalactosamine (GalNAc) = 1:5:4:3:1 (29)). For one experiment pooled 157 
human saliva from ten healthy volunteers was collected using Salivette (Sarstedt, 158 
Nümbrecht, Germany). After centrifugation with 1500 x g for 2 minutes samples were pooled 159 
and sterile filtrated with 0.22μm centrifugal filter units (Millipore, Billerica, MA) at 5000 x G for 160 
20 minutes as previously described (30). 161 
Capsules of strains grown in different growth media were released by overnight incubation in 162 
1% phenol, separated from the bacteria by centrifugation and filtration, and then purified with 163 
sodium acetate/ethanol precipitation, followed by protease and nuclease digestion of 164 
remaining contaminants, and finally cut-off filtrated as described (25). The extracted 165 
polysaccharides were then completely hydrolyzed by trifluoroacetic acid (TFA) (31). The 166 
monosaccharide composition of capsular polysaccharides of strains grown in CDM was 167 
determined by high performance liquid chromatography (HPLC) analysis of fluorescently 168 
labelled monosaccharides as previously described (25, 32-35), whereas the PIM extracts 169 
were analyzed on a system consisting of an  ASI-100 autosampler and P680 HPLC pump 170 
(DIONEX, Sunnyvale, CA, USA) with an injection volume of 20 µL per sample. Separation of 171 
the monosaccharide was done with a flow rate of 0.85 mL/min as follows: 6% solvent B 172 
isocratic for 35 minutes followed by a linear gradient from 6 to 12% solvent B over 20 173 
minutes. Then, the column was washed with 100% solvent B for 10 minutes and 100% 174 
solvent A for 15 minutes followed before re-equilibrating the system with 6% solvent B for 10 175 
minutes. Total run time was 90 minutes and data was collected for 55 minutes using an L-176 
7480 Fluorescence Detector (Merck Hitachi, Darmstadt, Germany). A Luna 5 mm, C18 177 
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column (Phenomenex, Torrance, CA) was used for separation and column temperature was 178 
maintained at 24 °C using a TCC-100 column oven (Thermo Scientific Dionex, Reinach, 179 
Switzerland). Peaks were identified by comparing retention time with monosaccharide 180 
standards analyzed in the same run (Figure S1A). As N-acetylated aminosugars are 181 
deacetylated during hydrolysis with TFA (36), deacetylated aminosugars were used as 182 
standards for their acetylated counterpart (e.g., mannosamine for N-acetyl-mannosamine). 183 
Negative controls included in each experiment were medium negative control for growth, 184 
extraction, hydrolysis and HPLC. HPLC raw data was exported into GraphPad Prism 185 
(Version 5, GraphPad Software, Inc.) for creating figures.  186 
Gas chromatography – mass spectrometry (GC-MS). GC-MS analysis of alditol acetates 187 
of the polysaccharide hydrolysates from strains 109.44 grown in PIM and 501.24 grown in 188 
PIM, pooled saliva, and CDM glucose was performed as a control, as previously described 189 
(37, 38).  190 
Nuclear magnetic resonance spectroscopy (NMR). NMR data were collected on a Bruker 191 
Avance II (500 MHz; 1H) spectrometer equipped with a 1.7 mm triple-resonance (1H, 13C, 192 
31P) microprobe head. The samples were extracted as described above and prepared as 193 
follows: The full amount of each capsule extract (~4 – 5 mg) was dissolved in 50 µl of D2O 194 
and 40 µl of the resulting mixtures were transferred into 1.7 mm NMR tubes. The water 195 
resonance was suppressed using a classical presaturation scheme. HSQC spectra were 196 
collected on a Bruker Avance III HD (600 MHz) spectrometer equipped with an inverse 5mm 197 
TCI helium cryoprobe. All spectra were acquired at a regulated temperature of 298 K and 198 
calibrated to the residual water peak (4.766 ppm). For the interpretation of the received 199 
carbon and hydrogen shifts, results from previous studies were used as guidance for the 200 
capsule structure determination of the 19A capsule extracts (4, 39, 40). 201 
 202 
  203 
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RESULTS 204 
Epidemiology of non-invasive 19A subtypes. We first aimed at analyzing the distribution 205 
of the different pneumococcal serotype 19A subtypes within the Swiss Sentinel Network 206 
collection of upper respiratory tract isolates. PCV7 had been recommended in Switzerland 207 
since late 2005 to all children under the age of 24 months in a three dose schedule given at 208 
2, 4 and 12 months and since August 2006 the vaccine has been fully reimbursed by the 209 
mandatory Swiss health insurance. Serotype 19A strains isolated from the upper respiratory 210 
tract between 1998 and 2011 were analyzed. In total, 158 19A isolates were screened for 211 
the three described subtypes using a two-step PCR protocol described above. Between 212 
1998 and 2005, we identified 30 (57.7%), 5 (9.6%) and 17 (32.7%) isolates belonging to 213 
subgroups 19A-I, 19A-II, and 19A-III, respectively. After 2006 until 2011, a significant relative 214 
difference was noted overall (p=0.02) but also individually for the subgroups 19A-I (p=0.02) 215 
and 19A-II (p=0.02) as 40 (37.7%), 28 (26.4%) and 38 (35.8%) isolates were detected with 216 
the 19A-I, 19A-II, and 19A-III subtypes, respectively (Figure 1A). There was still a significant 217 
shift even after data from the PCV7 introduction year (2006) were excluded (p=0.03). We 218 
found no evidence for a difference of 19A subtypes distribution according to age (Pre versus 219 
post introduction of PC7 eras over age groups of ≤1, 2-4, 5-15 and >15 years; Fisher’s exact 220 
test; p= 0.3). In addition, there was no indication of a time trend for the frequency of 19A 221 
subtypes before the PCV7 was present (Data not shown). As for molecular types derived by 222 
plyNCR-RFLP typing, plyNCR-RLPF types 1 (55.7%) and 16 (18.4%) were the most 223 
frequent within the 158 strains but we did not detect a significant shift of molecular types 224 
between pre and post PCV7 introduction era (Figure 1B). In addition we revealed that 225 
antibiotic resistances within the 19A strains were generally high and that 19A II is 226 
significantly more susceptible towards penicillin, erythromycin, and SXT as compared to the 227 
other subtypes (Figure 1C). However, calculating a multivariate logistic regression model  we 228 
confirmed that there was strong evidence that, compared to 19A I, the odds of observing 229 
subtype 19A II after introduction of PCV7 was 6 times higher than before PCV7, and that this 230 
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association was independent of antimicrobial resistance, geographical region, age or sex 231 
(p = 0.005; Table S1). 232 
We then selected at least one strain of each subtype for further laboratory analysis to 233 
determine capsular composition of the different subtypes (Table 1). Selected subtype strains 234 
represented different genetic backgrounds as indicated by MLST and plyNCR-RFLP 235 
analysis (Table 1). 236 
Method validation. To assess the degree of contamination of capsule extracts with cell wall 237 
and other components, we first compared the monosaccharide composition of hydrolyzed 238 
capsule extracts of a serotype 19F clinical isolate B201.73 with extracts of its isogenic 239 
capsule knockout mutant (B201.73∆cps) by HPLC with fluorescence detection (Figure S1B). 240 
No rhamnose peaks were detected for the strain without a capsule, but small amounts of 241 
glucose and higher amounts of amino sugars including mannosamine could be detected, 242 
most likely deriving from cell wall polysaccharide (CWPS) and from murein layer. 243 
Furthermore, hydrolysis with TFA is known to produce varying amounts of hydrolysis-derived 244 
(di)saccharides (Figure S1B). This contamination was usually present in capsule extracts 245 
from tested strains and was higher in amount as compared to the commercially available 246 
purified pneumococcal polysaccharide (Figure 2). Furthermore, after complete hydrolysis a 247 
linkage analysis is not possible and only monosaccharide determination can be done (e.g., 248 
same chromatogram for serotype 19A and 19F). Therefore, we used the HPLC method only 249 
as a screening tool for additional neutral monosaccharides under different growth conditions 250 
(i.e. galactose and fucose).  251 
Capsule composition analysis of 19A subtypes by HPLC and GC-MS. We then analyzed 252 
the capsule composition of a strain for each subgroup (109.44 and 501.14 (subtype 19A-I), 253 
501.24 (subtype 19A-II), and Hungary-19A-6 and 412.49 (subtype 19A-III) grown in CDM 254 
supplemented with 55 mM glucose. We did not detect additional neutral monosaccharides 255 
and comparison of the used isolates revealed no differences among the strains indicating 256 
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the same monosaccharide backbone built of glucose, rhamnose and (N-acetyl)-257 
mannosamine. As expected, HPLC chromatograms were not able to differentiate 19A from 258 
19F as both serotypes contain the same monosaccharide compositions (Figure 2A). We 259 
then analyzed the capsular extracts from the ATCC standard (Figure 2B) and from 19A 260 
subtypes grown in the undefined medium PIM (Figure 2C). Again, no additional neutral 261 
monosaccharides were detected and thus reported additional monosaccharides (galactose 262 
and fucose would have been expected on the neutral side based on the literature (6)) were 263 
not seen in our preparations. As HPLC allows only the identification of peaks based on their 264 
retention time in comparison to standards, the presence of the neutral monosaccharides in 265 
capsule extracts was confirmed for 109.44 (19A-I) grown in CDM with 55 mM Glucose 266 
(Figure S3A) and PIM (Figure S3B) and 501.24 (19A-II) grown in PIM (Figure S3C) with GC-267 
MS (which revealed glucose and rhamnose in all preparations). GC-MS also confirmed a 268 
lower degree of contamination with cell wall and other compounds in the ATCC standard 269 
compared to subtype capsule extracts (Figure S3D). 270 
To mimic saccharide nutrients present in the natural human environment of S. pneumoniae, 271 
109.44 (19A-I) was grown in CDM with monosaccharides contained in human mucin (5.5 272 
mM total concentration of the mucin building monosaccharides in ratios as determined for 273 
the salivary mucin MG1) and 501.24 (19A-II) was also grown in pooled human saliva 274 
collected from 10 healthy volunteers after sterile filtration. No additional neutral 275 
monosaccharides were identified to be present in the polysaccharide capsule extracted from 276 
the strains grown under these conditions compared to capsule extracted from strains grown 277 
in CDM supplemented with glucose or PIM but the signal to noise ratio was much lower in 278 
saliva grown capsule (Figure S2 and S3E). 279 
NMR analyses reveal no structural difference between subtypes. 280 
In order to confirm the proposed structures of the oligosaccharides we compared the 281 
anomeric region (4.8-6.0 ppm) in the 1H-NMR of all strains grown in CDM supplemented with 282 
55mM glucose (Figure 3A). We were able to clearly differentiate the capsule of serotype 19A 283 
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strains from 19F capsule. Comparison of carbon and hydrogen shifts with previously 284 
reported NMR spectra confirmed the following structures for serotype 19F: →2)-α-L-Rha-285 
(1→PO4→4)-β-D-ManNAc-(1→4)-α-D-Glc-(1→  and for serotype 19A: →3)-α-L-Rha-286 
(1→PO4→4)-β-D-ManNAc-(1→4)-α-D-Glc-(1→ . In addition, no differences among the 287 
serotypes 19A subtypes were detected. We then performed an identical 1H-NMR analysis of 288 
all strains grown in PIM which has been reported to alter the composition of 19A capsule (6). 289 
The spectra were again consistent within 19A subtypes but different from serotype 19F 290 
capsular polysaccharide (Figure 3A). Based on those results, it can be stated that the 291 
capsule composition is independent of tested growth medium as the patterns were identical 292 
to each other and to the ATCC reference 19A polysaccharide. Only a slight shift was 293 
observed for the capsule analysis of the Hungary 19A-6 strain. However, the overlay of the 294 
2D 1H-13C HSQC-NMR spectra of this isolate grown in PIM and CDM supplemented with 295 
glucose revealed identical patterns for the H-atoms of the anomeric region as illustrated for 296 
rhamnose, N-acetyl mannosamine and glucose (Figure 3B). The full 2D Spectrum is shown 297 
in Figure S4. 298 
  299 
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DISCUSSION 300 
In this study we demonstrated that the distribution of pneumococcal serotype 19A subtypes 301 
changed after the implementation of PCV7 in Switzerland. However, all analyzed capsular 302 
extracts from serotype 19A subtypes grown in defined medium CDM and the undefined 303 
medium PIM showed a capsule composition which was consistent with the one proposed 304 
based on genetic analysis. Furthermore, we did not find any evidence for additional side 305 
chains altered repeat units or linkage changes under different nutritional conditions. .  306 
During the time of widespread use of PCV7 in Switzerland the serotype 19A subtype 307 
distribution changed substantially compared to the pre-vaccine period. Similar shifts with 308 
decreasing 19A-I and increasing 19A-II subtypes after the introduction of PCV7 have also 309 
been reported in the Netherlands (19). Furthermore, although classified as group III by PCR, 310 
based on its genome sequence the Hungary 19A-6 strain contains an additional insertion 311 
element downstream of the last cps gene (rmlD) and differs from the subgroup III strains as 312 
defined by Elberse et al. (19) which could suggest an additional serotype 19A subgroup.  313 
Given the identical capsule structure for all tested 19A subtypes as revealed for the first time 314 
in our study using NMR, HPLC and GC-MS, no alteration of vaccine effectiveness due to 315 
capsular differences between individual subtypes is suggested. Furthermore, the lack of anti-316 
19F antibody cross-protection against serotype 19A can therefore not be explained by 317 
selection of 19A subtypes with altered capsule structures which supports recent discoveries 318 
suggesting a general low protection due to conformational difference in polysaccharide 319 
structures of 19F and 19A (17, 18).  320 
 321 
However, other factors could explain the observed subtype shift after the introduction of 322 
PCV7 in Switzerland. For example, changes in 19A subtypes could be due to changes in 323 
clonal distribution although we did not detect a significant shift of molecular types as 324 
determined by plyNCR-RFLP. However, additional typing methods or whole genome 325 
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sequencing might be more appropriate to investigate this hypothesis.  As for antibiotic 326 
resistance being a potential driver for the subtype shifts, we revealed that 19A II is 327 
significantly more susceptible to antibiotics as compared to the other subtypes indeed, but 328 
as 19A II increases in the PCV7 era, increasing antibiotic resistance can therefore not 329 
explain the changes in the distribution, though antibiotic resistance within serotype 19A 330 
strains is generally high as previously shown (41). A subtype redistribution under increasing 331 
vaccine selection pressure after the introduction of PCV13 would be unexpected, although it 332 
has been speculated that there might be a difference in capsule thickness for different 333 
subtypes which might lead to differences in opsonophagocytotic susceptibility (19).  334 
Previously reported experiments showing additional side chains in 19A isolates grown in PIM 335 
could not be replicated (6).  An explanation for this finding might be a strain-specific genetic 336 
alteration in previous studies. Indeed, it has been recently reported that serotype 11D has 337 
two different capsular polysaccharide repeating units in a ratio of 1:3 (25% and 75%, 338 
respectively) due to a bispecific transferase WcrL (42). Although precursors of capsular 339 
galactose and N-acetyl-glucosamine might be available due to their synthesis in other 340 
pathways (43), the (environment-dependent) addition of 2 side chains comprised of three 341 
additional monosaccharides is expected to be reflected with at least additional 342 
glycosyltransferase enzymes within the capsule locus involved in their linkage, and a switch 343 
of the glycosidic linkage between rhamnose and glucose would suggest mutations resulting 344 
in bispecificity or two copies of the wzy polymerase (3). To our knowledge, neither of these 345 
two possibilities have been detected in 19A strains (3). However, variation of the repeat unit 346 
structure would be suspected to have an influence on the antigenicity thus resulting in 347 
suspect serotyping results (i.e., less reactive with anti-19A antiserum) which were not 348 
observed in this study. However, given the increasing vaccine selection pressure after the 349 
introduction of PCV13, we recommend capsule structure determination of emerging clones 350 
and/or serotypes given recent discoveries of novel serotypes and capsule variants (42, 44-351 
47). The importance of chemical capsule structure analysis is also highlighted by a recent 352 
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analysis of serotype “6E” capsule, demonstrating that this potential new serotype determined 353 
at the genetic level produces capsular polysaccharide identical to 6B capsular 354 
polysaccharide (48). 355 
A particular strength of this study is the use of multiple techniques for capsule structure 356 
determination, which enhances the reliability of reported findings. We first used an HPLC 357 
based approach to determine if additional neutral sugars were incorporated into the capsule 358 
and validated the methodology with GC-MS. As this technique requires complete hydrolysis 359 
a linkage analysis was not possible in this first step. Furthermore, although this method has 360 
been demonstrated to have high normalized recoveries of neutral monosaccharides 361 
rhamnose and glucose of serotype 19F monosaccharides (32), TFA hydrolysis has also 362 
been reported to be less satisfactory for polysaccharides with aminosugar moieties (32) and 363 
it has been reported that disaccharides can be formed during hydrolysis based on different 364 
stability of intramolecular bonds (32) which also occurred in our experiments. 365 
Results showed traces of contamination of cell-wall components in our preparations, which 366 
is a common co-extracted compound in pneumococcal capsule preparations probably 367 
because the capsule is covalently linked to the cell wall (32, 49, 50). To determine linkage 368 
analysis and further characterization of the capsule oligosaccharide repeat units, we 369 
performed additional 1D and 2D NMR analysis of polysaccharides from unhydrolyzed 370 
capsule extracts. The major limitation of this study is that the number of different 19A 371 
subtype strains analyzed was rather small. However, we chose at least one sample of each 372 
of the currently known subtypes and it can therefore be expected that our study is 373 
representative. Although we did not find evidence for nutrition-dependent variations of 374 
capsule structures, this cannot be considered as final proof for an absence of such 375 
variations. Furthermore, we did not have the same strains or capsule extracts for which a 376 
nutrient-dependent variation has been reported as a reference for the assays used (6).  377 
In summary, the polysaccharide capsule composition for tested serotype 19A subtypes was 378 
consistently composed of the same trisaccharide repeat unit. Although we therefore do not 379 
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expect a structural advantage for certain subtypes it remains to be determined how the 19A 380 
subtype distribution will be affected by PCV13. We did not detect any nutritional 381 
environment-dependent alterations of the capsule composition. However, given the genetic 382 
plasticity of S. pneumoniae and current vaccine selection pressure, we propose to test the 383 
capsule composition of emerging serotype 19A clones, especially in cases where there is no 384 
other explanation for a selective advantage such as antibiotic resistance or loss or 385 
acquisition of other virulence factors.  386 
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TABLE 1. Streptococcus pneumoniae strains used in this study 558 
ID Serotype Subtype* plyNCR-RFLP** MLST 
109.44 19A 19A-I 16 ST 276 
501.14 19A 19A-I 1 ST 416 
501.24 19A 19A-II 1 ST 199 
412.49 19A 19A-III 14 ST 1151 
Hungary 19A-6 
(ATCC 700673) 
19A 19A-III  20 ST 268*** 
505.32 19F 19F 4 ST 179 
B201.73 19F 19F 40 ST 43 
 559 
ND: Not done; MLST: Multi Locus Sequencing Typing; ST: Sequence Type; RFLP: 560 
Restriction Fragment Length Polymorphism 561 
* Defined as previous described (19) 562 
** Done as previously described (21). 563 
*** According to: http://spneumoniae.mlst.net/sql/fulldetails.asp?id=689 564 
 565 
 566 
 567 
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FIGURE LEGENDS 569 
FIGURE 1. A. Epidemiology of 19A subtypes (19A-I, 19A-II, and 19A-III) 1998-2011. A 570 
total of 158 serotype 19A strains isolated within the Swiss Sentinel Network (outpatients with 571 
upper respiratory tract infections) were analyzed. 1998-2005 was considered as pre-572 
conjugate vaccine (PCV7) era. The % of tested isolates and subgroup assignment for both 573 
periods is shown. There was an overall significance as derived by Fisher exact test 574 
(P=0.02). Chi-Square test revealed significant changes in relative frequency between the 575 
two periods for subtypes 19A-I (p=0.02) and 19A-II (p=0.02). 95% confidence intervals (CI) 576 
are indicated. B. Distribution of molecular types as determined by plyNCR-RFLP 1998-577 
2011. Shown are the most frequent plyNCR-RFLP types (Types 1 and 16). The remaining 578 
types were pooled within ‘others’. There was no overall significance as derived by Fisher 579 
exact test for the two different eras. 95% confidence intervals (CI) are indicated. C. 580 
Antibiotic resistance of serotype 19A isolates against penicillin, erythromycin, and 581 
sulfamethoxazole / trimethoprim (SXT), 1998-2011. Minimum inhibitory concentration 582 
(MIC) for penicillin non-susceptibility was ≥ 0.06 mg/L while for erythromycin and SXT the 583 
disk diffusion method was performed (intermediate and resistant were considered as non-584 
susceptible. 19A II is significantly more susceptible towards penicillin (Fisher exact test; p< 585 
0.001), erythromycin (p= 0.014), and SXT (p< 0.001) as compared to the other subtypes. 586 
95% confidence intervals (CI) are indicated. 587 
FIGURE 2. HPLC chromatograms of serotype 19A subtypes and 19F strain B201.73 588 
grown in CDM and PIM. HPLC composition analysis of hydrolyzed polysaccharide capsule 589 
of clinical isolates of serotype 19A subtypes grown in chemically defined medium with 55 590 
mM glucose (A) compared to ATCC purified pneumococcal serotype 19A polysaccharide 591 
(B), and the pneumococcal inoculation medium PIM (C). Y-axis shows fluorescence (FU) 592 
and chromatograms were stacked to facilitate comparison. Peaks of mannosamine (Man-N), 593 
rhamnose (Rha) and glucose (Glc) are labeled. 594 
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FIGURE 3. A. 1D NMR spectra of serotype 19A subtypes. Shown are 1H NMR spectra of 595 
capsular polysaccharide puriﬁed from each subtype grown in CDM 55 mM glucose (black) 596 
and PIM (red) compared to serotype 19F and ATCC 19A purified pneumococcal 597 
polysaccharide. B. 2D NMR. Shown is a superimposition of 1H-13C HSQC-NMR spectra of 598 
the anomeric region from PS from Hungary 19A-6 capsule grown in CDM and PIM.  599 
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